China Diabetes Devices - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2024 - 2029)

The China Diabetes Devices Market size is estimated at USD 7.43 billion in 2024, and is expected to reach USD 9.33 billion by 2029, growing at a CAGR of 4.66% during the forecast period (2024-2029).

China has witnessed a significant rise in the prevalence of diabetes in recent decades, posing a major public health challenge for the nation. This surge in diabetes cases can be primarily attributed to factors such as rapid urbanization, sedentary lifestyles, unhealthy dietary habits, and an aging population. According to data from the International Diabetes Federation (IDF), China has the highest number of adults diagnosed with diabetes worldwide, surpassing 100 million individuals.

As the diabetes epidemic continues to unfold, there has been a corresponding increase in the demand for diabetes devices. These devices play a crucial role in managing diabetes by equipping individuals with tools to monitor their blood glucose levels, administer insulin, and track their overall health. Glucose meters, insulin pumps, continuous glucose monitoring (CGM) systems, and insulin pens are among the commonly used devices in diabetes management.

The growing population of individuals with diabetes in China has stimulated innovation and investment in the diabetes devices market. Both domestic and international manufacturers are capitalizing on this escalating demand by introducing advanced technologies and expanding their range of products. Chinese companies are leveraging their expertise in manufacturing and research to develop cost-effective devices that cater to the specific needs of the local population.

Furthermore, the Chinese government has acknowledged the pressing need to tackle the diabetes crisis and has introduced a range of measures to enhance diabetes management and prevention. These initiatives involve raising public awareness, advocating for healthy lifestyles, improving healthcare access, and providing subsidies for diabetes devices to low-income individuals.

In conclusion, the expanding diabetes population in China is propelling the growth of the diabetes devices market, emphasizing innovation, affordability, and accessibility. Dealing with the diabetes epidemic necessitates a holistic approach that covers prevention, early detection, and effective management strategies. By investing in diabetes prevention and treatment, China can alleviate the disease's impact and enhance the health and well-being of its populace.

China Diabetes Devices Market Trends

Monitoring Devices Market is growing with the highest CAGR in forecast period

Patients diagnosed with type-1 diabetes (T1D) are tasked with maintaining a healthy lifestyle, a challenge influenced by individual personality traits, social interactions, socioeconomic circumstances, and environmental factors. The integration of continuous glucose monitoring (CGM) alongside multiple daily injections (MDI) has proven effective in reducing both non-severe and severe hypoglycemia among individuals with T1 diabetes prone to such events. Remarkably, even amidst the challenging conditions imposed by the severe lockdown during the COVID-19 pandemic crisis, patients at high risk of hypoglycemia managed to control their blood sugar levels through standalone continuous glucose monitoring.

Managing viral infections in individuals with diabetes poses challenges due to variations in blood glucose (BG) levels. Real-time continuous glucose monitoring (RT-CGM) enables the monitoring of BG trends, allowing for intervention to prevent drastic fluctuations before they lead to complications. The Dexcom G4 Platinum CGM system's impressive range of up to 6.0 meters reduces the need for medical personnel to enter isolation rooms, enhancing safety protocols.

These advancements contribute to the growth of the monitoring device market in China. The increasing number of generic manufacturers in the country aligns with the growing preference among type-1 diabetes patients for cost-effective treatments, thereby supporting the expansion of the market under scrutiny.

Increasing Type -1 Diabetes Population in China

According to estimates, 1 in 10 Chinese citizens have diabetes. During the 21st Century, millions of new cases of diabetes are occurring each year. However, a precise statistic for diabetes in China is difficult to calculate because many cases remain undetected. China is believed to have surpassed India as the country with the most significant diabetes population in the world.

Diabetes is most prevalent in China's cities, where economic growth is accelerating, and traditional dietary patterns are rapidly eroding. According to China health experts, the fundamental causes of this diabetes number spike include urbanization, improving living standards, and an aging population. According to the National Health Commission, China has made steps to reduce diabetic and high blood pressure patients' medical expenses by reimbursing outpatients for more than half of their medication costs (NHC).

According to the National Metabolic Disease Clinical Research Center, more hospitals in China will establish National Metabolic Management Centers (MMC) as part of their exploration of a new model of diabetes treatment. According to the National Health Commission, China Statistics, MMCs have provided services for more than 200,000 patients over the last two years.

As a result, the diabetes care market in China is predicted to expand gradually in the coming years.

China Diabetes Devices Industry Overview

The new technologies in diabetes devices, like continuous glucose monitoring, have increased the market for monitoring devices. The mergers and acquisitions between the players, like the acquisition of TypeZero Technologies by Dexcom, are paving the way for automated insulin delivery. The acquisition has sent Dexcom ahead on its way in the race to create an artificial pancreas system rather than merely offering a boost to the continuous glucose monitoring device market.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

This product will be delivered within 2 business days.